STRS Ohio’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-46,000
| Closed | -$73K | – | 2142 |
|
|
2024
Q1 | $73K | Sell |
46,000
-2,900
| -6% | -$4.3K | ﹤0.01% | 1724 |
|
|
2023
Q4 | $42K | Hold |
48,900
| – | – | ﹤0.01% | 1802 |
|
|
2023
Q3 | $52K | Hold |
48,900
| – | – | ﹤0.01% | 1788 |
|
|
2023
Q2 | $126K | Buy |
48,900
+3,800
| +8% | +$13.6K | ﹤0.01% | 1693 |
|
|
2023
Q1 | $184K | Hold |
45,100
| – | – | ﹤0.01% | 1610 |
|
|
2022
Q4 | $226K | Hold |
45,100
| – | – | ﹤0.01% | 1563 |
|
|
2022
Q3 | $589K | Sell |
45,100
-2,100
| -4% | -$31.8K | ﹤0.01% | 1250 |
|
|
2022
Q2 | $605K | Buy |
47,200
+2,300
| +5% | +$31.9K | ﹤0.01% | 1251 |
|
|
2022
Q1 | $684K | Hold |
44,900
| – | – | ﹤0.01% | 1294 |
|
|
2021
Q4 | $795K | Buy |
44,900
+11,800
| +36% | +$226K | ﹤0.01% | 1280 |
|
|
2021
Q3 | $695K | Sell |
33,100
-8,500
| -20% | -$187K | ﹤0.01% | 1366 |
|
|
2021
Q2 | $820K | Buy |
41,600
+18,900
| +83% | +$442K | ﹤0.01% | 1308 |
|
|
2021
Q1 | $659K | Buy |
22,700
+7,400
| +48% | +$207K | ﹤0.01% | 1447 |
|
|
2020
Q4 | $463K | Hold |
15,300
| – | – | ﹤0.01% | 1507 |
|
|
2020
Q3 | $243K | Hold |
15,300
| – | – | ﹤0.01% | 1618 |
|
|
2020
Q2 | $302K | Buy |
15,300
+2,000
| +15% | +$38.2K | ﹤0.01% | 1532 |
|
|
2020
Q1 | $163K | Hold |
13,300
| – | – | ﹤0.01% | 1591 |
|
|
2019
Q4 | $245K | Buy |
13,300
+11,500
| +639% | +$168K | ﹤0.01% | 1636 |
|
|
2019
Q3 | $24K | Hold |
1,800
| – | – | ﹤0.01% | 1965 |
|
|
2019
Q2 | $26K | Buy |
+1,800
| New | +$26.3K | ﹤0.01% | 2007 |
|
STRS Ohio's NGM Position: Q2 2024 in Review
STRS Ohio sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 46,000 shares — an estimated $73K sold.
STRS Ohio first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $820K in Q2 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- STRS Ohio reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- STRS Ohio sold 46,000 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $73K.
- STRS Ohio first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- STRS Ohio's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $820K in Q2 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on STRS Ohio's 13F filing for Q2 2024, filed 5 Aug 2024.